Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab

BACKGROUND: KRAS mutations have been characterized as the major predictive biomarkers for resistance to cetuximab treatment. However, studies indicate that not all KRAS mutations are associated with equivalent treatment outcomes. KRAS G13D mutations were observed to account for approximately 16% of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hangyu, Yuan, Liyun, Liu, Lulu, Yan, Cong, Cheng, Jinming, Fu, Qihan, Tong, Zhou, Jiang, Weiqin, Zheng, Yi, Zhao, Peng, Zhang, Guoqing, Fang, Weijia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222508/
https://www.ncbi.nlm.nih.gov/pubmed/32404198
http://dx.doi.org/10.1186/s12885-020-06909-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222508/
https://www.ncbi.nlm.nih.gov/pubmed/32404198
http://dx.doi.org/10.1186/s12885-020-06909-y

Ejemplares similares